{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:09:59Z","timestamp":1793639399128,"version":"4.5.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) is characterized by dysregulated interferon (IFN) signaling. Despite its importance, a comprehensive and systematic synthesis of available data is lacking and findings across studies have been inconsistent. To address this gap, a systematic review and meta-analysis was conducted to evaluate global variations in IFN\u03b1, IFN-\u03b3, and some important cytokines in adult SLE cases compared to healthy controls (HCs). Furthermore, we assessed their association with disease activity and effect of detection methods, sample types, and regional variations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search was conducted in PubMed and Scopus as primary databases, with Google Scholar used as a supplementary search engine, using MeSH terms and keywords related to SLE and IFNs (up to 15 November 2024). The Quantitative synthesis was performed using Comprehensive Meta-Analysis, calculating standardized mean differences (SMD) with 95% confidence intervals (CI) using a random-effects model for continuous outcomes. Correlation data were analyzed using Fisher\u2019s\n                      <jats:italic>z<\/jats:italic>\n                      transformation. Publication bias was accessed using funnel plots and Egger\u2019s test. For heterogeneity, Cochrane\u2019s\n                      <jats:italic>Q<\/jats:italic>\n                      test,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistic, subgroup analyses, sensitivity analyses, and Bayesian meta-analysis were conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 33 eligible studies, comparing IFN levels among 2307 SLE patients and 1599 HCs were included. Significantly elevated levels of IFN\u03b1 (SMD\u2009=\u20091.428, 95%CI [0.78, 2.08],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and IFN\u03b3 (SMD\u2009=\u20090.922, 95%CI [0.32, 1.52],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) in SLE patients compared with HCs were observed. Elevated levels of IFN\u03b3 were correlated with disease activity (SMD\u2009=\u20090.609, 95%CI [0.30, 0.91],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Additionally, significantly elevated levels of key pro-inflammatory cytokines, including IL-6 (SMD\u2009=\u20090.679, 95%CI [0.45, 0.90],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and TNF\u03b1 (SMD\u2009=\u20091.754, 95%CI [0.25, 3.26],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022), were observed. Subgroup analyses revealed that differences in detection method, sample type, and geographic regions could influence measured cytokine levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The elevated IFN levels in SLE patients, with a significant correlation of IFN\u03b3 with disease activity, suggest their role in disease pathogenesis and potential as a biomarker for monitoring disease activity. The findings identify IFNs and key pro-inflammatory cytokines as potential therapeutic targets. Given the limitations of our study, future research employing robust study designs and methodologies are warranted to increase the reliability of our findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42023445357.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04318-1","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:40:59Z","timestamp":1759916459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Unravelling the connection between interferons and systemic lupus erythematosus: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Ridi","family":"Khatri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Khargekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyasi","family":"Athalye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Rajadhyaksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Padwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-8059","authenticated-orcid":false,"given":"Vandana","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"7","key":"4318_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076578","volume":"24","author":"D Accapezzato","year":"2023","unstructured":"Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L, Paroli M. Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci. 2023;24(7): 6578. https:\/\/doi.org\/10.3390\/ijms24076578.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"4318_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914413","volume":"24","author":"P Richter","year":"2023","unstructured":"Richter P, Macovei LA, Mihai IR, Cardoneanu A, Burlui MA, Rezus E. Cytokines in systemic lupus erythematosus-focus on TNF-\u03b1 and IL-17. Int J Mol Sci. 2023;24(19): 14413. https:\/\/doi.org\/10.3390\/ijms241914413.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4318_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00296-023-05346-x","volume":"43","author":"A Akhil","year":"2023","unstructured":"Akhil A, Bansal R, Anupam K, Tandon A, Bhatnagar A. Systemic lupus erythematosus: latest insight into etiopathogenesis. Rheumatol Int. 2023;43(8):1381\u201393. https:\/\/doi.org\/10.1007\/s00296-023-05346-x.","journal-title":"Rheumatol Int"},{"key":"4318_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.rcreu.2021.05.018","volume":"28","author":"KL Rinc\u00f3n-Delgado","year":"2021","unstructured":"Rinc\u00f3n-Delgado KL, Tovar-S\u00e1nchez C, Fern\u00e1ndez-\u00c1vila DG. Role of cytokines in the pathophysiology of systemic lupus erythematosus. Revista Colombiana de Reumatolog\u00eda. 2021;28:144\u201355. https:\/\/doi.org\/10.1016\/j.rcreu.2021.05.018.","journal-title":"Revista Colombiana de Reumatolog\u00eda"},{"issue":"1","key":"4318_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16(1):19\u201330. https:\/\/doi.org\/10.1007\/s12519-019-00229-3.","journal-title":"World J Pediatr"},{"issue":"7","key":"4318_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"CC Mok","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481\u201390. https:\/\/doi.org\/10.1136\/jcp.56.7.481.","journal-title":"J Clin Pathol"},{"key":"4318_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.33590\/emjrheumatol\/10311457","volume":"5","author":"M Rojas","year":"2018","unstructured":"Rojas M, Rodr\u00edguez Y, Leon KJ, Pacheco Y, Acosta-Ampudia Y, Monsalve DM, Ram\u00edrez-Santana C, Anaya JM. Cytokines and inflammatory mediators in systemic lupus erythematosus. EMJ Rheumatology. 2018;5:83\u201392. https:\/\/doi.org\/10.33590\/emjrheumatol\/10311457.","journal-title":"EMJ Rheumatology"},{"key":"4318_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01292","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H, Wang J, Xia Y. Defective suppressor of cytokine signaling 1 signaling contributes to the pathogenesis of systemic lupus erythematosus. Front Immunol. 2017;8: 1292. https:\/\/doi.org\/10.3389\/fimmu.2017.01292.","journal-title":"Front Immunol"},{"key":"4318_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/432595","volume":"2011","author":"K Ohl","year":"2011","unstructured":"Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011: 432595. https:\/\/doi.org\/10.1155\/2011\/432595.","journal-title":"J Biomed Biotechnol"},{"issue":"10","key":"4318_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/jir.2011.0029","volume":"31","author":"SA Apostolidis","year":"2011","unstructured":"Apostolidis SA, Lieberman LA, Kis-Toth K, Crisp\u00edn JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31(10):769\u201379. https:\/\/doi.org\/10.1089\/jir.2011.0029.","journal-title":"J Interferon Cytokine Res"},{"key":"4318_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954706","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu W, Zhang S, Wang J. IFN-\u03b3, should not be ignored in SLE. Front Immunol. 2022;13: 954706. https:\/\/doi.org\/10.3389\/fimmu.2022.954706.","journal-title":"Front Immunol"},{"issue":"9","key":"4318_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090963","volume":"8","author":"IT Chyuan","year":"2019","unstructured":"Chyuan IT, Tzeng HT, Chen JY. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells. 2019;8(9): 963. https:\/\/doi.org\/10.3390\/cells8090963.","journal-title":"Cells"},{"issue":"5","key":"4318_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/mr\/roac140","volume":"33","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Kusuda M, Yamaguchi Y. Interferons and systemic lupus erythematosus: pathogenesis, clinical features, and treatments in interferon-driven disease. Mod Rheumatol. 2023;33(5):857\u201367. https:\/\/doi.org\/10.1093\/mr\/roac140.","journal-title":"Mod Rheumatol"},{"key":"4318_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1046687","volume":"13","author":"S Bruera","year":"2023","unstructured":"Bruera S, Chavula T, Madan R, Agarwal SK. Targeting type I interferons in systemic lupus erythematous. Front Pharmacol. 2023;13: 1046687. https:\/\/doi.org\/10.3389\/fphar.2022.1046687.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4318_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","volume":"6","author":"L R\u00f6nnblom","year":"2019","unstructured":"R\u00f6nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1): e000270. https:\/\/doi.org\/10.1136\/lupus-2018-000270.","journal-title":"Lupus Sci Med"},{"issue":"10","key":"4318_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1089\/jir.2011.0047","volume":"31","author":"LS Davis","year":"2011","unstructured":"Davis LS, Hutcheson J, Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31(10):781\u20139. https:\/\/doi.org\/10.1089\/jir.2011.0047.","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"4318_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000625","volume":"9","author":"M Northcott","year":"2022","unstructured":"Northcott M, Jones S, Koelmeyer R, Bonin J, Vincent F, Kandane-Rathnayake R, Hoi A, Morand E. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci Med. 2022;9(1): e000625. https:\/\/doi.org\/10.1136\/lupus-2021-000625.","journal-title":"Lupus Sci Med"},{"issue":"9","key":"4318_CR18","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1002\/art.22044","volume":"54","author":"X Feng","year":"2006","unstructured":"Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2951\u201362. https:\/\/doi.org\/10.1002\/art.22044.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4318_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/08916930310001625952","volume":"36","author":"MK Crow","year":"2003","unstructured":"Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36(8):481\u201390. https:\/\/doi.org\/10.1080\/08916930310001625952.","journal-title":"Autoimmunity"},{"issue":"6","key":"4318_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.20021553","volume":"197","author":"L Bennett","year":"2003","unstructured":"Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711\u201323. https:\/\/doi.org\/10.1084\/jem.20021553.","journal-title":"J Exp Med"},{"issue":"5","key":"4318_CR21","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610\u20135. https:\/\/doi.org\/10.1073\/pnas.0337679100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4318_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/nep.12047","volume":"18","author":"DY Yap","year":"2013","unstructured":"Yap DY, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside. Nephrology. 2013;18(4):243\u201355. https:\/\/doi.org\/10.1111\/nep.12047.","journal-title":"Nephrology"},{"issue":"21","key":"4318_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111327","volume":"22","author":"H Idborg","year":"2021","unstructured":"Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21): 11327. https:\/\/doi.org\/10.3390\/ijms222111327.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4318_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2029-1","volume":"21","author":"N Ruchakorn","year":"2019","unstructured":"Ruchakorn N, Ngamjanyaporn P, Suangtamai T, Kafaksom T, Polpanumas C, Petpisit V, Pisitkun T, Pisitkun P. Performance of cytokine models in predicting SLE activity. Arthritis Res Ther. 2019;21(1): 287. https:\/\/doi.org\/10.1186\/s13075-019-2029-1.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4318_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1666-0","volume":"20","author":"JA Reynolds","year":"2018","unstructured":"Reynolds JA, McCarthy EM, Haque S, Ngamjanyaporn P, Sergeant JC, Lee E, Lee E, Kilfeather SA, Parker B, Bruce IN. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018;20(1): 173. https:\/\/doi.org\/10.1186\/s13075-018-1666-0.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4318_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2217\/ijr.15.17","volume":"10","author":"HA Kim","year":"2015","unstructured":"Kim HA, Jung JY, Suh CH. Biomarkers for systemic lupus erythematosus: an update. Int J Clin Rheumatol. 2015;10(3):195.","journal-title":"Int J Clin Rheumatol"},{"key":"4318_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"4318_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1): 210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"4318_CR29","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"7109","key":"4318_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"13","key":"4318_CR31","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/sim.1461","volume":"22","author":"N Terrin","year":"2003","unstructured":"Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22(13):2113\u201326. https:\/\/doi.org\/10.1002\/sim.1461.","journal-title":"Stat Med"},{"key":"4318_CR32","doi-asserted-by":"publisher","DOI":"10.1201\/9780429258411","volume-title":"Bayesian data analysis","author":"A Gelman","year":"1995","unstructured":"Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis. Chapman and Hall\/CRC; 1995."},{"issue":"4","key":"4318_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/jrsm.1475","volume":"12","author":"C R\u00f6ver","year":"2021","unstructured":"R\u00f6ver C, Bender R, Dias S, Schmid CH, Schmidli H, Sturtz S, Weber S, Friede T. On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. Res Synth Methods. 2021;12(4):448\u201374. https:\/\/doi.org\/10.1002\/jrsm.1475.","journal-title":"Res Synth Methods"},{"key":"4318_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100092","volume":"4","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhou T, Wu H, Zhao M, Lu Q. Difference of ifi44l methylation and serum IFN-a1 level among patients with discoid and systemic lupus erythematosus and healthy individuals. J Transl Autoimmun. 2021;4: 100092. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100092.","journal-title":"J Transl Autoimmun"},{"issue":"5","key":"4318_CR35","first-page":"646","volume":"14","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Zhao Y, Mo X. Expression of lncRNA NEAT1 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus and its correlation with Th1\/Th2 balance. Int J Clin Exp Pathol. 2021;14(5):646\u201352.","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"4318_CR36","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.4049\/jimmunol.2000222","volume":"205","author":"M Li","year":"2020","unstructured":"Li M, Yang C, Wang Y, Song W, Jia L, Peng X, Zhao R. The expression of P2X7 receptor on Th1, Th17, and regulatory T cells in patients with systemic lupus erythematosus or rheumatoid arthritis and its correlations with active disease. J Immunol. 2020;205(7):1752\u201362. https:\/\/doi.org\/10.4049\/jimmunol.2000222.","journal-title":"J Immunol"},{"issue":"1","key":"4318_CR37","first-page":"36","volume":"36","author":"S Wen","year":"2018","unstructured":"Wen S, He F, Zhu X, Yuan S, Liu H, Sun L. IFN-\u03b3, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36(1):36\u201343.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"4318_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/08820139.2018.1527852","volume":"48","author":"V Kailashiya","year":"2019","unstructured":"Kailashiya V, Singh U, Rana R, Singh NK, Dash D, Kailashiya J. Regulatory t cells and their association with serum markers and symptoms in systemic lupus erythematosus and rheumatoid arthritis. Immunol Invest. 2019;48(1):64\u201378. https:\/\/doi.org\/10.1080\/08820139.2018.1527852.","journal-title":"Immunol Invest"},{"issue":"13","key":"4318_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.4103\/0366-6999.235110","volume":"131","author":"XY Luo","year":"2018","unstructured":"Luo XY, Yuan JL, Liu J, Luo CN, Yang MH, Wei Q, Yang M, Chen Y, Liu Y, Yuan GH. Increased macroautophagy in interferon-gamma-producing T cells from patients with newly diagnosed systemic lupus erythematosus. Chin Med J (Engl). 2018;131(13):1527\u201332. https:\/\/doi.org\/10.4103\/0366-6999.235110.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"4318_CR40","first-page":"16658","volume":"8","author":"JB Wang","year":"2015","unstructured":"Wang JB, Li H, Wang LL, Liang HD, Zhao L, Dong J. Role of IL-1\u03b2, IL-6, IL-8 and IFN-\u03b3 in pathogenesis of central nervous system neuropsychiatric systemic lupus erythematous. Int J Clin Exp Med. 2015;8(9):16658\u201363.","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"4318_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00296-010-1636-6","volume":"32","author":"CY Ma","year":"2012","unstructured":"Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-\u03b1 and TNF-\u03b1 in systemic lupus erythematosus. Rheumatol Int. 2012;32(2):395\u2013402. https:\/\/doi.org\/10.1007\/s00296-010-1636-6.","journal-title":"Rheumatol Int"},{"issue":"6","key":"4318_CR42","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0961203311434937","volume":"21","author":"V Arora","year":"2012","unstructured":"Arora V, Verma J, Marwah V, Kumar A, Anand D, Das N. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects. Lupus. 2012;21(6):596\u2013603. https:\/\/doi.org\/10.1177\/0961203311434937.","journal-title":"Lupus"},{"issue":"2","key":"4318_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cyto.2010.02.017","volume":"50","author":"R Zhang","year":"2010","unstructured":"Zhang R, Xing M, Ji X, Gu L, Yang X, Wang H, Jiang P. Interferon-alpha and interleukin-6 in SLE serum induce the differentiation and maturation of dendritic cells derived from CD34+ hematopoietic precursor cells. Cytokine. 2010;50(2):195\u2013203. https:\/\/doi.org\/10.1016\/j.cyto.2010.02.017.","journal-title":"Cytokine"},{"issue":"6","key":"4318_CR44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S1007-4376(09)60086-1","volume":"23","author":"R Zhang","year":"2009","unstructured":"Zhang R, Xing M, Wang W, Yang X, Ji X. Effect of interferon-alpha in systemic lupus erthematosus (SLE) serum on the differentiation and maturation of dendritic cells derived from CD34+ hematopoietic precursor cells. J Nanjing Med Univ. 2009;23(6):380\u20135. https:\/\/doi.org\/10.1016\/S1007-4376(09)60086-1.","journal-title":"J Nanjing Med Univ"},{"issue":"2","key":"4318_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/ar2382","volume":"10","author":"SK Kwok","year":"2008","unstructured":"Kwok SK, Lee JY, Park SH, Cho ML, Min SY, Park SH, Kim HY, Cho YG. Dysfunctional interferon-\u03b1 production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(2): R29. https:\/\/doi.org\/10.1186\/ar2382.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4318_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1878-y","volume":"21","author":"V Oke","year":"2019","unstructured":"Oke V, Gunnarsson I, Dorschner J, Eketj\u00e4ll S, Zickert A, Niewold TB, Svenungsson E. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1): 107. https:\/\/doi.org\/10.1186\/s13075-019-1878-y.","journal-title":"Arthritis Res Ther"},{"key":"4318_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cyto.2018.11.008","volume":"114","author":"DC Salazar-Camarena","year":"2019","unstructured":"Salazar-Camarena DC, Ort\u00edz-Lazareno P, Mar\u00edn-Rosales M, Cruz A, Mu\u00f1oz-Valle F, Tapia-Llanos R, Orozco-Barocio G, Machado-Contreras R, Palafox-S\u00e1nchez CA. BAFF-R and TACI expression on CD3+ T cells: interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine. 2019;114:115\u201327. https:\/\/doi.org\/10.1016\/j.cyto.2018.11.008.","journal-title":"Cytokine"},{"issue":"2","key":"4318_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1515\/jomb-2017-0048","volume":"37","author":"L Zecevic","year":"2018","unstructured":"Zecevic L, Karamehic J, Coric J, Stubljar D, Avdagic N, Selmanovic K, Jukic T, Savic S. Potential immune biomarkers in diagnosis and clinical management for systemic lupus erythematosus. J Med Biochem. 2018;37(2):163\u201371. https:\/\/doi.org\/10.1515\/jomb-2017-0048.","journal-title":"J Med Biochem"},{"issue":"2","key":"4318_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0961203317716321","volume":"27","author":"SM Abdel Galil","year":"2018","unstructured":"Abdel Galil SM, El-Shafey AM, Abdul-Maksoud RS, El-Boshy M. Interferon alpha gene expression and serum level association with low vitamin D levels in Egyptian female patients with systemic lupus erythematosus. Lupus. 2018;27(2):199\u2013209. https:\/\/doi.org\/10.1177\/0961203317716321.","journal-title":"Lupus"},{"issue":"2","key":"4318_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejr.2021.10.004","volume":"44","author":"FH Abdelraouf","year":"2022","unstructured":"Abdelraouf FH, Ramadan ME, Abdulazim DO, Selim HM. Clinical significance of interferon lambda-3 (IFN\u03bb3)\/interleukin 28B (IL28B) in systemic lupus erythematosus patients. The Egyptian Rheumatologist. 2022;44(2):121\u20135. https:\/\/doi.org\/10.1016\/j.ejr.2021.10.004.","journal-title":"The Egyptian Rheumatologist"},{"issue":"1","key":"4318_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/aimj.2021.56633.1395","volume":"2","author":"AN Bayoumy","year":"2021","unstructured":"Bayoumy AN, Shalaby M, Eldahan M, Abdelaziz A, Metwaly I. Assessment of serum level of interferon gamma in patients of lupus nephritis and without nephritis. Al-Azhar International Medical Journal. 2021;2(1):1\u20136. https:\/\/doi.org\/10.21608\/aimj.2021.56633.1395.","journal-title":"Al-Azhar International Medical Journal."},{"issue":"4","key":"4318_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5114\/reum.2020.98434","volume":"58","author":"Y Adel","year":"2020","unstructured":"Adel Y, Sadeq Y. Impact of IL-34, IFN-\u03b1 and IFN-\u03bb1 on activity of systemic lupus erythematosus in Egyptian patients. Reumatologia. 2020;58(4):221\u201330. https:\/\/doi.org\/10.5114\/reum.2020.98434.","journal-title":"Reumatologia"},{"issue":"2","key":"4318_CR53","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000479319","volume":"24","author":"M Postal","year":"2017","unstructured":"Postal M, Ruocco HH, Brand\u00e3o CO, Costallat LTL, Silva L, Cendes F, Appenzeller S. Interferon-\u03b3 is associated with cerebral atrophy in systemic lupus erythematosus. Neuroimmunomodulation. 2017;24(2):100\u20135. https:\/\/doi.org\/10.1159\/000479319.","journal-title":"Neuroimmunomodulation"},{"key":"4318_CR54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00580-014-2018-3","volume":"24","author":"HA Rasol","year":"2015","unstructured":"Rasol HA, Gaber W, Aziz MA, Rabie AG. Elevated high-mobility group box1 level is associated with alterations of interferon gamma in Egyptians with lupus nephritis. Comp Clin Pathol. 2015;24:989\u201394. https:\/\/doi.org\/10.1007\/s00580-014-2018-3.","journal-title":"Comp Clin Pathol"},{"key":"4318_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109239","volume":"247","author":"FK Alduraibi","year":"2023","unstructured":"Alduraibi FK, Sullivan KA, Chatham WW, Hsu HC, Mountz JD. Interrelation of T cell cytokines and autoantibodies in systemic lupus erythematosus: a cross-sectional study. Clin Immunol. 2023;247: 109239. https:\/\/doi.org\/10.1016\/j.clim.2023.109239.","journal-title":"Clin Immunol"},{"issue":"3","key":"4318_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/cei.12429","volume":"178","author":"K Santana-de Anda","year":"2014","unstructured":"Santana-de Anda K, G\u00f3mez-Mart\u00edn D, Monsivais-Urenda AE, Salgado-Bustamante M, Gonz\u00e1lez-Amaro R, Alcocer-Varela J. Interferon regulatory factor 3 as key element of the interferon signature in plasmacytoid dendritic cells from systemic lupus erythematosus patients: novel genetic associations in the Mexican mestizo population. Clin Exp Immunol. 2014;178(3):428\u201337. https:\/\/doi.org\/10.1111\/cei.12429.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"4318_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079414","volume":"8","author":"AL Fauchais","year":"2013","unstructured":"Fauchais AL, Lise MC, Marget P, Lapeybie FX, Bezanahary H, Martel C, Dumonteil S, Sparsa A, Lallou\u00e9 F, Ly K, Essig M, Vidal E, Jauberteau MO. Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study. PLoS One. 2013;8(11): e79414. https:\/\/doi.org\/10.1371\/journal.pone.0079414.","journal-title":"PLoS One"},{"key":"4318_CR58","doi-asserted-by":"publisher","unstructured":"Abdulridha RH, Saud AM, Alosami MH. Evaluation of interferon alpha (IFN-\u03b1) in women with systemic lupus erythematosus in Iraq. Iraqi Journal of Science. 2022:4225\u201333. https:\/\/doi.org\/10.24996\/ijs.2022.63.10.9.","DOI":"10.24996\/ijs.2022.63.10.9"},{"issue":"2","key":"4318_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2249.2008.03758.x","volume":"154","author":"M Tucci","year":"2008","unstructured":"Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008;154(2):247\u201354. https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03758.x.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4318_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2249.2004.02588.x","volume":"138","author":"N Calvani","year":"2004","unstructured":"Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol. 2004;138(1):171\u20138. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02588.x.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"4318_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.semarthrit.2003.11.002","volume":"33","author":"D G\u00f3mez","year":"2004","unstructured":"G\u00f3mez D, Correa PA, G\u00f3mez LM, Cadena J, Molina JF, Anaya JM. Th1\/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective? Semin Arthritis Rheum. 2004;33(6):404\u201313. https:\/\/doi.org\/10.1016\/j.semarthrit.2003.11.002.","journal-title":"Semin Arthritis Rheum"},{"key":"4318_CR62","doi-asserted-by":"publisher","unstructured":"Simon Q, Grasseau A, Boudigou M, Le Pottier L, Bettachioli E, Cornec D, Rouvi\u00e8re B, Jamin C, Le Lann L, PRECISESADS Clinical Consortium, PRECISESADS Flow Cytometry Study Group, Borghi MO, Aguilar-Quesada R, Renaudineau Y, Alarc\u00f3n-Riquelme ME, Pers JO, Hillion S. A proinflammatory cytokine network profile in Th1\/type 1 effector B cells delineates a common group of patients in four systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(8):1550\u20131561. https:\/\/doi.org\/10.1002\/art.41697.","DOI":"10.1002\/art.41697"},{"issue":"1","key":"4318_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43166-023-00215-8","volume":"50","author":"M Nasser","year":"2023","unstructured":"Nasser M, Wadie M, Farid A, Amir AE. Nailfold capillaroscopy in Egyptian systemic lupus erythematosus (SLE) patients: correlation with demographic features and serum levels of IL 17A and IFNs I. Egypt Rheumatol Rehabil. 2023;50(1):47. https:\/\/doi.org\/10.1186\/s43166-023-00215-8.","journal-title":"Egypt Rheumatol Rehabil"},{"issue":"1","key":"4318_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21608\/smj.2022.131134.1314","volume":"26","author":"AT Mostafa","year":"2022","unstructured":"Mostafa AT, Abd Allah AA, Hafez R, Hussien S, Bakry RM. Interleukin-4, and interferon-gamma roles as biomarkers in systemic lupus erythematosus patients. Sohag Medical Journal. 2022;26(1):51\u20139. https:\/\/doi.org\/10.21608\/smj.2022.131134.1314.","journal-title":"Sohag Medical Journal"},{"issue":"4","key":"4318_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jksus.2022.102007","volume":"34","author":"A Farid","year":"2022","unstructured":"Farid A, Hany A, Khaled A, Safwat G. Cytokines and autoantibodies profile during systemic lupus erythematosus and psoriasis diseases in Egypt. J King Saud Univ. 2022;34(4): 102007. https:\/\/doi.org\/10.1016\/j.jksus.2022.102007.","journal-title":"J King Saud Univ"},{"issue":"4","key":"4318_CR66","first-page":"535","volume":"20","author":"P Amerio","year":"2002","unstructured":"Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pit\u00e0 O, Puddu P. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol. 2002;20(4):535\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"4318_CR67","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1177\/09612033221102575","volume":"31","author":"SS Pattanaik","year":"2022","unstructured":"Pattanaik SS, Panda AK, Pati A, Padhi S, Tripathy R, Tripathy SR, Parida MK, Das BK. Role of interleukin-6 and interferon-\u03b1 in systemic lupus erythematosus: a case-control study and meta-analysis. Lupus. 2022;31(9):1094\u2013103. https:\/\/doi.org\/10.1177\/09612033221102575.","journal-title":"Lupus"},{"issue":"20","key":"4318_CR68","doi-asserted-by":"publisher","first-page":"11286","DOI":"10.3390\/ijms222011286","volume":"22","author":"M Ramaswamy","year":"2021","unstructured":"Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci. 2021;22(20):11286. https:\/\/doi.org\/10.3390\/ijms222011286.","journal-title":"Int J Mol Sci"},{"issue":"5\u20136","key":"4318_CR69","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00011-022-01554-6","volume":"71","author":"N Bolouri","year":"2022","unstructured":"Bolouri N, Akhtari M, Farhadi E, Mansouri R, Faezi ST, Jamshidi A, Mahmoudi M. Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm Res. 2022;71(5\u20136):537\u201354. https:\/\/doi.org\/10.1007\/s00011-022-01554-6.","journal-title":"Inflamm Res"},{"key":"4318_CR70","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2020\/e1801","volume":"75","author":"J Ding","year":"2020","unstructured":"Ding J, Su S, You T, Xia T, Lin X, Chen Z, Zhang L. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics (Sao Paulo). 2020;75: e1801. https:\/\/doi.org\/10.6061\/clinics\/2020\/e1801.","journal-title":"Clinics (Sao Paulo)"},{"key":"4318_CR71","doi-asserted-by":"publisher","first-page":"9952463","DOI":"10.1155\/2021\/9952463","volume":"2021","author":"R Yin","year":"2021","unstructured":"Yin R, Xu R, Ding L, Sui W, Niu M, Wang M, Xu L, Wang H, Srirat C. Circulating IL-17 level is positively associated with disease activity in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:9952463. https:\/\/doi.org\/10.1155\/2021\/9952463.","journal-title":"Biomed Res Int"},{"issue":"12","key":"4318_CR72","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716\u201330. https:\/\/doi.org\/10.1038\/nrrheum.2016.186.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"4318_CR73","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.5858\/arpa.2019-0519-CP","volume":"144","author":"V Knight","year":"2020","unstructured":"Knight V, Long T, Meng QH, Linden MA, Rhoads DD. Variability in the laboratory measurement of cytokines. Arch Pathol Lab Med. 2020;144(10):1230\u20133. https:\/\/doi.org\/10.5858\/arpa.2019-0519-CP.","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"4318_CR74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.trsl.2009.08.012","volume":"155","author":"SN Kariuki","year":"2010","unstructured":"Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res. 2010;155(3):109\u201317. https:\/\/doi.org\/10.1016\/j.trsl.2009.08.012.","journal-title":"Transl Res"},{"issue":"10","key":"4318_CR75","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.rceng.2023.11.001","volume":"223","author":"A Gonz\u00e1lez-Garc\u00eda","year":"2023","unstructured":"Gonz\u00e1lez-Garc\u00eda A, Cus\u00e1covich I, Ruiz-Irastorza G. Treatment of systemic lupus erythematosus: new therapeutic options. Rev Clin Esp (Barc). 2023;223(10):629\u201339. https:\/\/doi.org\/10.1016\/j.rceng.2023.11.001.","journal-title":"Rev Clin Esp (Barc)"},{"issue":"12","key":"4318_CR76","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1080\/14728222.2020.1832464","volume":"24","author":"LM Mathias","year":"2020","unstructured":"Mathias LM, Stohl W. Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets. 2020;24(12):1283\u2013302. https:\/\/doi.org\/10.1080\/14728222.2020.1832464.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"4318_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/ijmm.2022.5098","volume":"49","author":"F Ghorbaninezhad","year":"2022","unstructured":"Ghorbaninezhad F, Leone P, Alemohammad H, Najafzadeh B, Nourbakhsh NS, Prete M, Malerba E, Saeedi H, Tabrizi NJ, Racanelli V, Baradaran B. Tumor necrosis factor-\u03b1 in systemic lupus erythematosus: structure, function and therapeutic implications (review). Int J Mol Med. 2022;49(4):43. https:\/\/doi.org\/10.3892\/ijmm.2022.5098.","journal-title":"Int J Mol Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04318-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:41:01Z","timestamp":1759916461000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04318-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4318"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04318-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"543"}}